• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

UroGen Pharma raises $75M

March 18, 2021 By Sean Whooley

UroGen PharmaUroGen Pharma (NSDQ:URGN) announced today that it entered into a funding agreement with RTW Investments worth $75 million.

Princeton, N.J.-based UroGen’s agreement with RTW will see the biopharmaceutical company receive $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto (mitomycin) for pyelocalyceal solution, as well as UGN-102 (also mitomycin), if approved, according to a news release.

In exchange for the upfront payment, RTW’s future cash payments hinge on the annual sales of Jelmyto ranging from high to low single-digits based on certain annual sales thresholds, which are subject to upward adjustment if certain sales and regulatory milestones are not met.

Future payments for both Jelmyto and UGN-102 will terminate following the date that RTW has received an aggregate amount pursuant to the payments of $300 million.

UroGen develops the RTGel reverse-thermal hydrogel which is a proprietary sustained release, hydrogel-based platform technology designed to improve the therapeutic profiles of existing drugs. The sustained release technology can enable longer exposure of the urinary tract tissue to medications to make local therapy a potentially more effective option.

UGN-102, the company’s first commercial product, is designed for the intravesical treatment of patients with low-grade non-muscle invasive bladder cancer. It is designed to ablate tumors by non-surgical means.

“UroGen’s RTGel platform has demonstrated the ability to overcome historical treatment barriers, work with anatomical complexity and thus unlock new therapeutic potential, including those conditions targeted by Jelmyto and UGN-102,” RTW Investments managing director of strategic finance Brad Sitko said in the release. “We are proud to partner with the UroGen management team and look forward to supporting the company’s goal of building a leading uro-oncology company.”

“This important non-dilutive transaction provides a clear path to fund the ongoing launch of Jelmyto and to advance our UGN-102 program, including the ongoing Phase 3 ATLAS study,” added UroGen Pharma CFO Molly Henderson. “We are proud to partner with RTW, a leading, research-driven healthcare investor, allowing us to access capital that is aligned with our vision and invest further in our mission of developing treatments for patients with urologic and specialty cancers.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Hydrogels, Immunotherapy Tagged With: UroGen Pharma

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS